vimarsana.com

Latest Breaking News On - Entrectinib rozlytrek - Page 1 : vimarsana.com

Entrectinib by F Hoffmann-La Roche for Metastatic Uveal Melanoma: Likelihood of Approval

FDA Expands Entrectinib Indication in Pediatric Patients With NTRK+ Solid Tumors

The FDA has granted accelerated approval to entrectinib (Rozlytrek) for pediatric patients aged older than 1 month with solid tumors that harbor a NTRK gene fusion without a known acquired resistance mutation, are metastatic, or where surgical resection is likely to result in severe morbidity, and have progressed after treatment or have no satisfactory standard therapy options.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.